Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | Clinical Drug Investigation
Neratinib for breast cancer – the key is managing gastrointestinal toxicity | Cancer Biology
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting | Business Wire
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
Puma Biotechnology Surging
NERATINIB, HKI 272, ..Puma presents positive results from phase II trial of its investigational drug PB272 | New Drug Approvals
Neratinib - Wikipedia
Nerlynx: Package Insert - Drugs.com
Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia | Future Oncology
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 | Business Wire
Mechanism of action | NERLYNX® (neratinib) tablets
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | The Motley Fool
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Puma Biotechnology
Neratinib for HER2-positive breast cancer with an overlooked option | Molecular Medicine | Full Text
FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies - Journal of Thoracic Oncology
Puma Biotechnology
